key: cord-0810308-mfu4s1aa
authors: Tanislav, Christian; Rosenbauer, Josef; Zingel, Rebecca; Kostev, Karel
title: No increased incidence of venous thrombosis or pulmonary embolism after SARS-CoV-2 vaccination in Germany
date: 2022-03-16
journal: Public Health
DOI: 10.1016/j.puhe.2022.03.004
sha: a1bf23fc00c78ca383c62af86495eb2304e5e626
doc_id: 810308
cord_uid: mfu4s1aa

Objectives Vaccination is one of the most effective measures to combat the COVID-19 pandemic. The main reason for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination hesitancy is the potential side effects. This study aimed to investigate the incidence of venous thrombosis and pulmonary embolism in patients who received SARS-CoV-2 vaccination. Study design Retrospective cohort study. Methods Individuals aged ≥18 years who received an initial vaccination for COVID-19 in one of 1134 general practices in Germany between April and June 2021 were included in the study. Vaccinated patients were matched to unvaccinated individuals by age, sex, index month (April to June 2020 [unvaccinated cohort] or April to June 2021 [vaccinated cohort]) and diagnoses that may be associated with an increased incidence of thrombosis documented within 12 months prior to the index date. The incidences of thrombosis and non-fatal pulmonary embolism as a function of COVID-19 vaccination were analysed. Results The present study included 326,833 individuals who were vaccinated against COVID-19 and 326,833 matched unvaccinated individuals. During the follow-up period, 406 vaccinated patients and 342 individuals in the control group received a diagnosis of thrombosis or non-fatal pulmonary embolism. This resulted in an incidence rate of 11.9 vs. 11.3 cases per 1000 patient years for vaccinated vs. unvaccinated individuals, respectively, and a non-significant overall incidence rate ratio (IRR: 1.06; 95% confidence interval [CI]: 0.93–1.22). The highest IRR was observed in the 41–60 years age group (IRR: 1.30; 95% CI: 0.98–1.73) and the lowest IRR was seen in the 18–40 years age group (IRR: 0.6; 95% CI: 0.0–1.05); however, none of the individual age group incidence rates were significant. Conclusions The results indicate that the occurrence of thrombosis or pulmonary embolism after COVID-19 vaccination is a coincidental finding rather than a consequence of vaccination.

The COVID-19 pandemic has had a dramatic impact worldwide, affecting both social lives and economic development (1) (2) (3) (4) (5) . Use of the recently developed vaccines has proven effective in combating the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and preventing severe outcomes of COVID-19 (6). However, vaccine hesitancy has been reported in many countries for a variety of reasons (7). While vaccine rollouts have increased over time, vaccination hesitancy has remained an issue (7, 8) . In addition to an obvious gap in vaccination rates between developed and developing countries, a similar trend has emerged regarding vaccine hesitancy, with factors such as higher education level, higher income, non-rural residency and free vaccination provision being identified as determinants for vaccine acceptance (7, 8) . Some investigations have indicated that a general trust in authorities and the government correlates strongly with willingness to be vaccinated (7). However, potential vaccine side effects have been identified as the most common reason for COVID-19 vaccine hesitancy and were cited by more than 90% of the vaccine hesitant individuals questioned (8, 9) . Common post-vaccination side effects, such as local reactions, fever, fatigue, headache or joint pain, are of minor relevance and are non-life threatening (10) . On the other hand, some events, such as autoimmune inflammatory neurological or vascular and haematological disorders, including myocardial infarction, thrombosis, cerebral vein thrombosis and thrombocytopenia, have been identified as having a potential association with the vaccine (11 − 15). However, reports of these types of serious adverse events in the literature are rare and their link to COVID-19 vaccination remains a topic of discussion (16). In the context of vaccine hesitancy and the global COVID-19 pandemic, it is important to investigate the incidence of such events using robust data, for example data derived from large-scale investigations.

Providing reliable evidence of the safety of COVID-19 vaccines may help to boost confidence and improve acceptance of these recently developed vaccines. Therefore, this study investigated the frequency of thrombosis and non-fatal pulmonary embolism in patients who received the SARS-CoV-2 vaccine. Data were obtained from a large database that is supplied with information from general practitioners (GPs) and specialists in Germany.

This study used data from the Disease Analyzer database (IQVIA), which contains drug prescriptions, diagnoses, and basic medical and demographic information that is obtained directly and in an anonymous format from computer systems used in the practices of GPs and specialists (17) . The database covers approximately 3% of all outpatient practices in Germany.

Diagnoses (according to International Classification of Diseases, 10th revision [ICD-10]), prescriptions (according to Anatomical Therapeutic Chemical [ATC] classification system) and the quality of the reported data is monitored regularly by IQVIA. In Germany, the sampling methods used to select physicians' practices are appropriate for obtaining a representative database of general and specialised practices. It has previously been shown that the panel of practices included in the Disease Analyzer database is representative of general and specialised practices in Germany (17) . In addition, this database has already been used in previous studies focusing on 19) as well as cardiovascular outcomes (20, 21) .

This retrospective cohort study included individuals aged ≥18 years who received a COVID-19 vaccination in one of 1134 general practices in Germany between April and June 2021 (index date; Figure 1 ). Individuals with thrombosis (ICD-10: I80-I82) or pulmonary embolism (ICD-10: I26) diagnoses within the 12 months prior to the index date were excluded, as were those diagnosed with COVID-19 either prior to the index date or during the follow-up period.

Vaccinated patients were matched to unvaccinated individuals on the basis of greedy nearestneighbour propensity scores derived from the logistic regression analysis using age, sex, index month (April, May, June), and diagnoses that may be associated with an increased incidence of thrombosis documented within 12 months prior to the index date, including obesity (CD-10: E66), atrial fibrillation (ICD-10: I48.0, I481, I48.2, I48.9), heart failure (ICD-10: I50), ischaemic heart diseases (ICD-10: i20-I25), cancer (ICD-10; C00-C97), coagulation defects (ICD-10: D65-D69), varicose (ICD-10: I83-I85), injuries (ICD-10: S00-T12, within 6 months), J o u r n a l P r e -p r o o f and status post-surgery (ICD-10: Z98, within 6 months). As only vaccination information from GPs and not from vaccination centres was available, unvaccinated individuals (the matched cohort) were selected based on a randomly selected visit date between April and June 2020, since no COVID-19 vaccinations were available during this period ( Figure 1 ).

The main outcome of the study was the incidence of thrombosis (ICD-10: I80-I82) and nonfatal pulmonary embolism (ICD-10: I26) diagnoses as a function of COVID-19 vaccination. Each individual was followed-up for a maximum of 122 days after the index date. Differences in the sample characteristics between vaccinated and unvaccinated individuals were analysed using

McNemar tests for categorical variables and paired sample Wilcoxon tests for continuous variables. Poisson regression models were used to obtain incidence rate ratios (IRRs), taking account of differential exposure times via offsets. Marginal models were estimated using the generalised estimation equations method to account for correlation of observations within matched pairs. P-values <0.05 were considered statistically significant. Analyses were carried out using SAS version 9.4 (SAS institute, Cary, USA).

The present study included 326,833 individuals who received a COVID-19 vaccination between April and June 2021, and 326,833 individuals with a GP visit between April and June 2020. The basic characteristics of the study participants are shown in Table 1 Pivotal trials for SARS-CoV-2 vaccines clearly demonstrate that the vaccines offer great efficacy in preventing severe outcomes of COVID-19 (22) (23) (24) (25) . In terms of safety, very few severe adverse events related to COVID-19 vaccination have been reported (22) (23) (24) (25) . Of the few severe events reported, the most noteworthy are several cases of peripheral facial nerve palsy, one case of transverse myelitis tinnitus and a number of cases of tinnitus (22) (23) (24) (25) . reporting 159 (34.6%) cases of cerebral vein thrombosis, followed by 67 venous thromboses (14.6%) and 63 cases (13.7%) of pulmonary embolism (11) . Thrombocytopenia was frequently observed in patients with post-vaccination thrombotic events, indicating that this phenomenon may be related to the still unclear pathological mechanism behind this adverse J o u r n a l P r e -p r o o f reaction (11) (12) (13) (14) (15) . However, the data presented on thrombotic and thromboembolic events after COVID-19 vaccination, such as thromboses or pulmonary embolism, are limited to anecdotal reports or case series. There is currently a lack of data on incidence rates for these events in vaccinated individuals compared with unvaccinated individuals to enable risk estimation.

Vein thrombosis and pulmonary embolism occur frequently in patients with predisposing risk factors. Furthermore, the intake of haemostasis-modulating drugs influences the occurrence of these events (25, 26) . The overall crude incidence rate of thrombotic and thromboembolic events in unselected adults is far lower, at around 1 in 1000 per year (27) . The current study participants (vaccinated and matched unvaccinated individuals) may have a low to medium risk of thrombotic and thromboembolic events due to selection bias when prioritising ill or vulnerable individuals for vaccination. However, we detected the same incidence rate in both the vaccinated and unvaccinated groups, which is a major finding of the present study. The incidences of thrombotic and thromboembolic events in the vaccination group detected in the current study represent the expected intrinsic rate in a low-to medium-risk population rather than a result of COVID-19 vaccination. However, although results of the current study clearly indicate that vaccination against COVID-19 is not a factor for facilitating thrombotic and thromboembolic events, these findings require verification in further large-scale investigations.

The two major strengths of this study are the number of patients available for analysis and the detailed analyses performed using real-world data. This study is also subject to several limitations that should be acknowledged. First, the thrombosis and pulmonary embolism diagnosis data relied solely on ICD-10 codes, and no data were available on the diagnosis process or the severity/activity of the disease. Second, since no information was available on behavioural factors (e.g., alcohol use, smoking, use of contraceptive drugs, sedentary lifestyle), the roles played by these factors could not be examined. Third, no hospital data were available and only outpatients were analysed; severe cases of both COVID-19 and thrombosis are treated in hospitals. Fourth, analyses were not stratified by vaccination manufacturer; however, >90% of patients in this study received the BNT162b2 vaccine, a COVID-19 mRNA vaccine. Fifth, injuries as risk factor for thromboses was not included in the J o u r n a l P r e -p r o o f match-pairs variables due to the very small number of individuals with documented injuries during the study period. Finally, the database does not contain data on mortality; thus, no fatal events could be analysed.

In this large-scale investigation examining the incidences of thrombosis and pulmonary embolism, no differences were detected between COVID-19 vaccinated and unvaccinated individuals. It is therefore very likely that when these conditions occur after SARS-CoV-2 vaccination, they are an inevitable part of the medical history of the individual rather than a consequence of vaccination.

The database used in this study includes only anonymised data in compliance with the regulations of the applicable data protection laws. German law allows the use of anonymous electronic medical records for research purposes under certain conditions. According to this legislation, it is not necessary to obtain informed consent from patients or approval from a medical ethics committee for this type of observational study that contains no directly identifiable data. Because patients were only queried as aggregates and no protected health information was available for queries, no Institutional Review Board approval was required for the use of this database or the completion of this study.

The authors received no funding for this study. 

Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study

A large scale meta-analytic atlas of mental health problems prevalence during the COVID-19 early pandemic

Fewer non-COVID-19 respiratory tract infections and gastrointestinal infections during the COVID-19 pandemic

Deciphering the impact of novel coronavirus pandemic on agricultural sustainability, food security, and socio-economic sectors-a review

The impact of the COVID-19 pandemic on socio-economic and sustainability

Determinants of COVID-19 Vaccine Acceptance among the Adult Population of Bangladesh Using the Health Belief Model and the Theory of Planned Behavior Model. Vaccines (Basel)

Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated? Vaccine

A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. Vaccines (Basel)

Cardiovascular and haematological events post COVID-19 vaccination: A systematic review

COVID-19 Vaccine-Related Thrombosis: A Systematic Review and Exploratory Analysis. Front Immunol

Thrombosis with

Thrombocytopenia Syndrome After Administration of AZD1222 or Ad26.COV2.S Vaccine for COVID-19: A Systematic Review

Post-SARS-CoV-2 vaccination venous sinus thrombosis: a literature review of 308

Basic Characteristics and Representativeness of the German Disease Analyzer Database

Fewer non-COVID-19 respiratory tract infections and gastrointestinal infections during the COVID-19 pandemic

Consultations Decline for Stroke, Transient Ischemic Attack, and Myocardial Infarction during the COVID-19 Pandemic in Germany

Late Detection of Atrial Fibrillation after Stroke: Implications for the Secondary Prevention

Increased Incidence of Stroke and Transient Ischemic Attack in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis in Germany

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil

High frequency of silent pulmonary embolism in patients with cryptogenic stroke and patent foramen ovale

Apixaban for extended treatment of venous thromboembolism